of Tissue Microarrays in the Evaluation of Focal Alterations of bcl-2 and p53 in Whole Mount Derived Prostate Tissues Vasectomy and Prostate Cancer
暂无分享,去创建一个
[1] M. Terris,et al. Vasectomy and prostate cancer characteristics of patients referred for prostate biopsy. , 2002, The Journal of urology.
[2] J. Oxley,et al. p53 and bcl‐2 immunohistochemistry in preoperative biopsies as predictors of biochemical recurrence after radical prostatectomy , 2002, BJU international.
[3] C. Paul,et al. High prevalence of vasectomy in New Zealand. , 2001, Contraception.
[4] F. Mostofi,et al. p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. , 1999, The Journal of urology.
[5] J. Kononen,et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.
[6] S. Groshen,et al. Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. , 1998, Journal of the National Cancer Institute.
[7] Yanping,et al. Loss of the Cyclin-dependent Kinase Inhibitor 27Kq Protein in Human Prostate Cancer Correlates with Tumor Grade’ , 2005 .
[8] J. Stanford,et al. Vasectomy and prostate cancer: a case-control study in a health maintenance organization. , 1996, American Journal of Epidemiology.
[9] J. Sandlow,et al. A change in practice: current urologic practice in response to reports concerning vasectomy and prostate cancer. , 1996, Fertility and sterility.
[10] A. Whittemore,et al. Vasectomy and prostate cancer: results from a multiethnic case-control study. , 1995, Journal of the National Cancer Institute.
[11] F. Speizer,et al. A retrospective cohort study of vasectomy and prostate cancer in US men. , 1993, JAMA.
[12] S. Shapiro,et al. Vasectomy and the risk of prostate cancer. , 1990, American journal of epidemiology.
[13] H Stein,et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. , 1984, Journal of immunology.
[14] A. Cesinaro,et al. Expression of p53 and bcl-2 in clinically localized prostate cancer before and after neo-adjuvant hormonal therapy. , 2000, Oncology research.